Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Abstract: The animal halter comprises a nose band sized to encircle the nose of the animal. The band has a top that aligns with the bridge of the nose of the animal, a bottom under the chin of the animal, and a left and right side. The nose band has one or more pressure protrusions. A crown-throat loop has one or more pressure protrusions and an optional brow band. The brow band may also have one or more pressure protrusions. The crown-throat loop has a top that aligns with the poll of the head of the animal, a bottom and a left and right side. A right cheek strap and a left cheek strap connect the sides of the nose band and the crown-throat loop. A chin-throat connecting piece connects the bottoms of the nose band and the crown-throat loop.

Abstract: The present invention relates to compositions, methods and uses of such compositions, the compositions comprising a pharmaceutically active compound and a non-encapsulating adjuvant, wherein the adjuvant comprises a fungal cell or a fragment thereof.

Abstract: An encapsulated product comprises a plurality of micro-capsules formed from a plurality of micro-organisms and having a lipophilic active encapsulated and passively retained within said micro-capsules. The lipophilic active is not being a natural constituent of the micro-organisms, and the micro-capsules has: (a) an at least substantially intact cell wall, and (b) an intact cell membrane. The micro-capsules are formulated to target delivery of the micro-capsules and the lipophilic active to at least one desired mucous membrane.